AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment ... While Bristol-Myers Squibb’s recent ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Some people who took a new schizophrenia drug for ... independent research team and shared by Bristol Myers Squibb showed the likelihood of continuing treatment. After six months, 36 said they ...

Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia ... stocks on TipRanks >> Read More on BMY: ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy ... discontinuation rates due to treatment-related or treatment-emergent adverse events (TEAE) stood at 11% and ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol ... Schizophrenia – A Network Meta-Analysis Current Estimates of the Incidence and Prevalence of Schizophrenia in the U.S. A full list of Bristol Myers ...

2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults PRINCETON, N.J., September 15, 2024--Bristol Myers Squibb ...

Bristol Myers Squibb (NYSE: BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY™ (xanomeline and ...